The systemic inflammatory response and its impact on iron nutriture in end-stage renal disease

被引:14
作者
Bistrian, BR [1 ]
Khaodhiar, L [1 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dept Med, Div Clin Nutr, Boston, MA 02215 USA
关键词
inflammatory response syndrome; systemic; dialysis; end-stage renal disease; tumor necrosis factor; iron;
D O I
10.1053/ajkd.1999.v34.aajkd0344b0035
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
In most chronic disease conditions, the systemic inflammatory response and its mediators play an essential pathogenic role. Protein calorie malnutrition, a prominent feature of end-stage renal disease (ESRD), also develops, largely as a consequence of the systemic inflammatory response. ESRD (uremia), dialysis, systemic metabolic acidosis, and infections activate the systemic inflammatory response. Elevations in C-reactive protein and depressions of serum albumin below 4 g/dL are found in more than 50% of ESRD patients undergoing dialysis. In many patients receiving dialysis, the impact of this acute-phase response on measures of iron metabolism limits the ability to diagnose iron deficiency. Furthermore, there are risks to iron administration, although data linking iron overload to risk of infection in dialysis patients is suggestive, not definitive. It seems reasonable to hypothesize that the greatest risk of iron administration is in patents who are already infected, and the greater risk would be to raise the serum iron level and transferrin saturation precipitously. The total-dose infusion method, which provides all iron required to correct deficiency in 1 dose, is more likely to produce side effects and rapidly raise serum iron levels and transferrin saturation. The use of low-dose intravenous iron supplementation (10 to 20 mg per dialysis treatment or 100 mg every second week) avoids iron overtreatment and should reduce adverse events. In ESRD patients receiving dialysis, the importance of the systemic inflammatory response in the development of protein calorie malnutrition, the impact of the acute-phase response on iron nutriture, and the response to erythropoietin therapy must be considered to achieve an understanding of the altered responses to nutritional therapy in this setting. (C) 1999 by the National Kidney Foundation, Inc.
引用
收藏
页码:S35 / S39
页数:5
相关论文
共 50 条
[1]   A randomized trial of three iron dextran infusion methods for anemia in EPO-treated dialysis patients [J].
Auerbach, M ;
Winchester, J ;
Wahab, A ;
Richards, K ;
McGinley, M ;
Hall, F ;
Anderson, J ;
Briefel, G .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 31 (01) :81-86
[2]  
BARRY DM, 1997, PEDIATRICS, V60, P908
[3]  
Bell Stacy J., 1996, Journal of Parenteral and Enteral Nutrition, V20, P43, DOI 10.1177/014860719602000143
[4]   The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin [J].
Besarab, A ;
Bolton, WK ;
Browne, JK ;
Egrie, JC ;
Nissenson, AR ;
Okamoto, DM ;
Schwab, SJ ;
Goodkin, DA .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (09) :584-590
[5]  
BEUTLER B, 1989, ANNU REV IMMUNOL, V7, P625, DOI 10.1146/annurev.iy.07.040189.003205
[6]   Tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-1 receptor antagonist in dialysate and serum from patients on continuous ambulatory peritoneal dialysis [J].
Brauner, A ;
Hylander, B ;
Wretlind, B .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (03) :402-408
[7]   TUMOR-NECROSIS-FACTOR ALPHA-PRODUCING CELLS IN THE INTESTINAL-MUCOSA OF CHILDREN WITH INFLAMMATORY BOWEL-DISEASE [J].
BREESE, EJ ;
MICHIE, CA ;
NICHOLLS, SW ;
MURCH, SH ;
WILLIAMS, CB ;
DOMIZIO, P ;
WALKERSMITH, JA ;
MACDONALD, TT .
GASTROENTEROLOGY, 1994, 106 (06) :1455-1466
[8]  
BULLEN JJ, 1981, REV INFECT DIS, V3, P1127
[9]  
BURNS DL, 1995, NUTRITION, V11, P163
[10]   Effect of iron-supplemented total parenteral nutrition in patients with iron deficiency anemia [J].
Burns, DL ;
Mascioli, EA ;
Bistrian, BR .
NUTRITION, 1996, 12 (06) :411-415